Teva Pharmaceutical Industries Limited
NYSE:TEVADrug Manufacturers - Specialty & Generic
-$1.09 today
- Market cap
- $49.28B
- Beta
- 0.85
- P/E (TTM)
- 23.1
- EPS (TTM)
- $1.36
Volume 8.86M
Average 6.22M
TEVA Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Teva Pharmaceutical Industries LimitedNYSE: TEVA
Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Investing cash flow turns negative
Q2 FY2026 investing cash flow was -$491M, compared with $236M a year earlier. Trailing-twelve-month investing cash flow was $38M. Over 3 fiscal years it compounded at +4.0% a year.
Context
- Investing cash flow amounted to 4.3% of revenue in FY2025, down 0.5 pp from a year earlier.
- Investing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly investing cash flow holds near -$491M or moves back toward the trailing-twelve-month quarterly average of $9.5M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 737M USD
- Year-over-year change
- -6.9%
- 4-year CAGR
- -16.6%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 737M | -6.9% |
| FY2024 | 2024-12-31 | 792M | -18.2% |
| FY2023 | 2023-12-31 | 968M | +47.6% |
| FY2022 | 2022-12-31 | 656M | -56.9% |
| FY2021 | 2021-12-31 | 1.52B | — |
Investing Cash Flow vs competitors
How TEVA compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -95.8% is the 4th highest of 5, against a peer median of +63.6%.
- Investing cash flow amounts to 0.2% of revenue for TEVA, versus a peer median of 8.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹31.03B INR | -34.7% | +19.5% | 9.4% | |
| LTM Jun 2026 | $212.37M USD | +161.8% | -13.6% | 6.8% | |
| LTM Mar 2026 | $130.02M USD | +263.3% | +17.9% | 23.2% | |
| LTM Jun 2026 | $84.3M USD | -105.8% | — | 0.6% | |
| LTM Jun 2026 | $38M USD | -95.8% | +4.0% | 0.2% | |
| Peer median (excluding TEVA) | — | +63.6% | +17.9% | 8.1% | |
Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 456M | (2.5B) | (615M) | (1.96B) | 1.42B |
| Depreciation & Amortization | 1.33B | 1.31B | 1.15B | 1.06B | 1B |
| Deferred Income Tax | (120M) | (1.06B) | (317M) | (634M) | (671M) |
| Stock-Based Compensation | 119M | 124M | 121M | 123M | 157M |
| Change in Working Capital | (1.7B) | 1.36B | (72M) | (435M) | (1.37B) |
| Accounts Receivables | (574M) | 334M | 12M | 245M | (173M) |
| Inventory | 380M | (163M) | (147M) | 166M | 152M |
| Accounts Payables | 764M | 2.01B | 1.59B | 258M | (15M) |
| Other Working Capital | (2.27B) | (828M) | (1.53B) | (1.1B) | (1.33B) |
| Other Non-Cash Items | 714M | 2.37B | 1.1B | 3.09B | 1.11B |
| Operating Cash Flow | 798M | 1.59B | 1.37B | 1.25B | 1.65B |
| Capital Expenditures | (562M) | (548M) | (526M) | (498M) | (501M) |
| Acquisitions (Net) | 1.96B | 61M | 68M | 28M | 34M |
| Purchases of Investments | (47M) | (1M) | (46M) | (71M) | (57M) |
| Sales of Investments | 172M | 4M | 0 | 40M | 42M |
| Other Investing Activities | 1M | 1.14B | 1.47B | 1.29B | 1.22B |
| Investing Cash Flow | 1.52B | 656M | 968M | 792M | 737M |
| Debt Repayment | (2.17B) | (1.37B) | (1.7B) | (1.64B) | (1.81B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6M) | (118M) | (212M) | (150M) | (337M) |
| Financing Cash Flow | (2.17B) | (1.49B) | (1.91B) | (1.79B) | (2.15B) |
| Effect of Forex Changes | (128M) | (123M) | (30M) | (175M) | 21M |
| Net Change in Cash | 21M | 636M | 393M | 73M | 256M |
| Free Cash Flow | 236M | 1.04B | 842M | 749M | 1.15B |
Teva Pharmaceutical Industries Limited
NYSE:TEVA
Intrinsic Alpha fair value
Locked
Current Price
$42.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.